{
  "run": {
    "id": "cmnr14o2t059sp65808ehl9ls",
    "region": "US",
    "assetId": "cmnr14o24059op658zzsg2vl7",
    "ticker": "MTD",
    "snapshotId": "cmnr14o2e059qp658oe884x0h",
    "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux",
    "createdAt": "2026-04-09T05:21:28.027Z",
    "promptTemplate": {
      "id": "cmnqt07si0005lm3jzpxuu1ux",
      "name": "Oficial 08.apr.2026",
      "version": 1
    },
    "snapshot": {
      "id": "cmnr14o2e059qp658oe884x0h",
      "assetId": "cmnr14o24059op658zzsg2vl7",
      "asOf": "2026-04-08T20:00:02.000Z",
      "snapshot": {
        "asOf": "2026-04-08T20:00:02.000Z",
        "quote": {
          "asOf": "2026-04-08T20:00:02.000Z",
          "open": null,
          "price": 1322.76,
          "dayLow": 1309.22,
          "volume": 112261,
          "dayHigh": 1327.02,
          "currency": "USD",
          "prevClose": 1270,
          "week52Low": 946.69,
          "week52High": 1525.17
        },
        "fundamentals": {
          "pe": 33.0611809343135,
          "beta": 1.12332793440738,
          "epsTTM": 42.17,
          "fcfTTM": 829275000,
          "growth": {
            "epsYoy": 0.03688222276862552,
            "revenueYoy": 0.03977883260367512
          },
          "sector": "Laboratory Analytical Instruments",
          "margins": {
            "net": 0.2158735386135353,
            "gross": 0.5937429449987446,
            "operating": null
          },
          "website": "http://mt.com",
          "industry": "Scientific instruments",
          "pegRatio": 8.96398819065684,
          "ebitdaTTM": 1169697000,
          "forwardPe": 30.434184675835,
          "marketCap": 24200000000,
          "totalCash": 66888000,
          "totalDebt": 2152172000,
          "debtEquity": -91.054831612794,
          "quickRatio": 0.7053832850909261,
          "revenueTTM": 4026399000,
          "companyName": "METTLER TOLEDO INTERNATIONAL INC/",
          "priceToBook": -1215.70990869479,
          "currentRatio": 1.13734145942463,
          "dividendYield": null,
          "returnOnAssets": 0.234116853586364,
          "returnOnEquity": -36.774115755627,
          "analystOpinions": null,
          "businessSummary": "Mettler Toledo, stylized in all caps, is a multinational supplier of precision instruments and services. The company focuses on laboratory, industrial, product inspection, and food retailing applications. Its products are used in research, quality control, and manufacturing processes in life sciences, food, chemical, and many other industries. The company's business is geographically diversified, with sales in 2023 derived 41% from North and South America, 27% from Europe, and 32% from Asia and other countries. The company’s global workforce consists of 17,300 employees as of December 31, 2023.",
          "enterpriseValue": 30819803401.91,
          "analystTargetLow": null,
          "analystTargetHigh": null,
          "analystTargetMean": null,
          "fullTimeEmployees": 17300,
          "sharesOutstanding": 20325250,
          "enterpriseToEbitda": 26.34853590452057,
          "analystTargetMedian": null,
          "enterpriseToRevenue": 7.654433502966298,
          "operatingCashflowTTM": 955772000,
          "analystRecommendationKey": null
        }
      },
      "createdAt": "2026-04-09T05:21:28.022Z"
    },
    "results": [
      {
        "id": "cmnr14o2y059up658ws2l53es",
        "runId": "cmnr14o2t059sp65808ehl9ls",
        "modelId": "anthropic",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MTD\",\"currency\":\"USD\",\"current_price\":1322.76,\"target_price_6m\":1360,\"target_price_12m\":1390,\"recommendation\":\"HOLD\",\"confidence\":0.62,\"thesis_bullets\":[\"Premium compounder with 59% gross margins but slowing top-line growth\",\"PEG ratio of ~9x signals valuation stretched relative to ~4% growth\",\"Negative shareholders equity from aggressive buybacks limits balance sheet flexibility\",\"China lab spending recovery pace remains uncertain, constraining near-term upside\",\"Strong FCF generation (~$830M TTM) supports continued capital returns\"],\"key_drivers\":[{\"driver\":\"China laboratory spending recovery trajectory\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pricing power sustaining gross margin near 59%\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Sluggish organic revenue growth (~4% YoY)\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Share repurchases boosting EPS despite low revenue growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Elevated net debt ($2.1B) with negative equity\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Service and recurring revenue mix shift\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Forward PE of 30x limits multiple expansion room\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Industrial end-market cyclical exposure\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Prolonged China demand weakness in biopharma and academic labs\",\"Multiple compression if EPS growth stays low-single-digits\",\"Rising interest expense on $2.15B debt with negative equity\",\"FX headwinds from strong USD on 59% international revenue\",\"Competitive pressure in product inspection and food retail segments\"],\"assumptions\":{\"revenue_cagr_3y\":0.055,\"ebit_margin_target\":0.27,\"wacc\":0.09,\"terminal_multiple\":28},\"scenarios\":{\"bear\":{\"target_price\":1100,\"prob\":0.2,\"notes\":\"China recovery stalls, multiple compresses to ~27x forward PE.\"},\"base\":{\"target_price\":1390,\"prob\":0.55,\"notes\":\"Mid-single-digit growth, stable multiples around 30x forward PE.\"},\"bull\":{\"target_price\":1600,\"prob\":0.25,\"notes\":\"China rebound accelerates organic growth to 7-8%, multiple expands.\"}},\"method_notes\":\"Blended forward PE and EV/EBITDA valuation. TTM EPS $42.17 grown ~5% to ~$44.3 at 30-31x forward PE yields ~$1,370-1,390 base. FCF yield ~3.4% offers limited margin of safety. PEG of ~9x signals growth premium is already priced in. Expected 12M return ~5% maps to HOLD per rubric given moderate uncertainty. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "ai-equity-research-v1",
          "risks": [
            "Prolonged China demand weakness in biopharma and academic labs",
            "Multiple compression if EPS growth stays low-single-digits",
            "Rising interest expense on $2.15B debt with negative equity",
            "FX headwinds from strong USD on 59% international revenue",
            "Competitive pressure in product inspection and food retail segments"
          ],
          "ticker": "MTD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.55,
              "notes": "Mid-single-digit growth, stable multiples around 30x forward PE.",
              "target_price": 1390
            },
            "bear": {
              "prob": 0.2,
              "notes": "China recovery stalls, multiple compresses to ~27x forward PE.",
              "target_price": 1100
            },
            "bull": {
              "prob": 0.25,
              "notes": "China rebound accelerates organic growth to 7-8%, multiple expands.",
              "target_price": 1600
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.09,
            "revenue_cagr_3y": 0.055,
            "terminal_multiple": 28,
            "ebit_margin_target": 0.27
          },
          "key_drivers": [
            {
              "driver": "China laboratory spending recovery trajectory",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pricing power sustaining gross margin near 59%",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Sluggish organic revenue growth (~4% YoY)",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Share repurchases boosting EPS despite low revenue growth",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Elevated net debt ($2.1B) with negative equity",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Service and recurring revenue mix shift",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Forward PE of 30x limits multiple expansion room",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Industrial end-market cyclical exposure",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Blended forward PE and EV/EBITDA valuation. TTM EPS $42.17 grown ~5% to ~$44.3 at 30-31x forward PE yields ~$1,370-1,390 base. FCF yield ~3.4% offers limited margin of safety. PEG of ~9x signals growth premium is already priced in. Expected 12M return ~5% maps to HOLD per rubric given moderate uncertainty. Not investment advice.",
          "current_price": 1322.76,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Premium compounder with 59% gross margins but slowing top-line growth",
            "PEG ratio of ~9x signals valuation stretched relative to ~4% growth",
            "Negative shareholders equity from aggressive buybacks limits balance sheet flexibility",
            "China lab spending recovery pace remains uncertain, constraining near-term upside",
            "Strong FCF generation (~$830M TTM) supports continued capital returns"
          ],
          "target_price_6m": 1360,
          "target_price_12m": 1390
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "anthropic",
            "webSearch": {
              "enabled": false,
              "maxToolCalls": 2,
              "disabledReason": null
            },
            "pauseTurns": 0,
            "stopReason": "end_turn"
          },
          "sanityIssues": []
        },
        "latencyMs": 31313,
        "createdAt": "2026-04-09T05:21:28.027Z",
        "usage": {
          "inputTokens": 3635,
          "outputTokens": 1494,
          "costUsd": 0.055525
        }
      },
      {
        "id": "cmnr14o2y059xp6587g1xjsil",
        "runId": "cmnr14o2t059sp65808ehl9ls",
        "modelId": "deepseek.reasoner",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"AI Equity Research Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"MTD\",\n  \"currency\": \"USD\",\n  \"current_price\": 1322.76,\n  \"target_price_6m\": 1335,\n  \"target_price_12m\": 1350,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.65,\n  \"thesis_bullets\": [\n    \"Stable demand in laboratory and industrial instruments.\",\n    \"High profitability with strong gross and net margins.\",\n    \"Moderate revenue growth in low single digits.\",\n    \"Elevated valuation multiples limit near-term upside.\",\n    \"Geographic diversification mitigates regional economic risks.\"\n  ],\n  \"key_drivers\": [\n    { \"driver\": \"Demand for precision instruments\", \"impact\": \"HIGH\", \"direction\": \"POS\" },\n    { \"driver\": \"Industrial automation adoption\", \"impact\": \"MED\", \"direction\": \"POS\" },\n    { \"driver\": \"Economic cycles affecting capital spending\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"Currency exchange rate fluctuations\", \"impact\": \"LOW\", \"direction\": \"NEG\" },\n    { \"driver\": \"Competition from lower-cost alternatives\", \"impact\": \"MED\", \"direction\": \"NEG\" },\n    { \"driver\": \"R&D innovation driving new product launches\", \"impact\": \"HIGH\", \"direction\": \"POS\" }\n  ],\n  \"risks\": [\n    \"Global economic downturn reducing instrument purchases\",\n    \"Increased competition eroding market share\",\n    \"Adverse currency movements impacting international sales\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.04,\n    \"ebit_margin_target\": 0.25,\n    \"wacc\": 0.075,\n    \"terminal_multiple\": 20\n  },\n  \"scenarios\": {\n    \"bear\": { \"target_price\": 1200, \"prob\": 0.2, \"notes\": \"Economic recession sharply cuts demand.\" },\n    \"base\": { \"target_price\": 1350, \"prob\": 0.6, \"notes\": \"Steady growth and margins persist.\" },\n    \"bull\": { \"target_price\": 1500, \"prob\": 0.2, \"notes\": \"Faster adoption in emerging markets boosts sales.\" }\n  },\n  \"method_notes\": \"DCF valuation with 4% revenue growth and 25% EBIT margin; current price near fair value implies HOLD. Not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "AI Equity Research Model",
          "risks": [
            "Global economic downturn reducing instrument purchases",
            "Increased competition eroding market share",
            "Adverse currency movements impacting international sales"
          ],
          "ticker": "MTD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady growth and margins persist.",
              "target_price": 1350
            },
            "bear": {
              "prob": 0.2,
              "notes": "Economic recession sharply cuts demand.",
              "target_price": 1200
            },
            "bull": {
              "prob": 0.2,
              "notes": "Faster adoption in emerging markets boosts sales.",
              "target_price": 1500
            }
          },
          "confidence": 0.65,
          "assumptions": {
            "wacc": 0.075,
            "revenue_cagr_3y": 0.04,
            "terminal_multiple": 20,
            "ebit_margin_target": 0.25
          },
          "key_drivers": [
            {
              "driver": "Demand for precision instruments",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Industrial automation adoption",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Economic cycles affecting capital spending",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Currency exchange rate fluctuations",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Competition from lower-cost alternatives",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "R&D innovation driving new product launches",
              "impact": "HIGH",
              "direction": "POS"
            }
          ],
          "method_notes": "DCF valuation with 4% revenue growth and 25% EBIT margin; current price near fair value implies HOLD. Not investment advice.",
          "current_price": 1322.76,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Stable demand in laboratory and industrial instruments.",
            "High profitability with strong gross and net margins.",
            "Moderate revenue growth in low single digits.",
            "Elevated valuation multiples limit near-term upside.",
            "Geographic diversification mitigates regional economic risks."
          ],
          "target_price_6m": 1335,
          "target_price_12m": 1350
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "endpoint": "https://api.deepseek.com/v1/chat/completions",
            "provider": "deepseek",
            "webSearch": {
              "enabled": false,
              "supported": false
            },
            "responseFormat": "json_object"
          },
          "sanityIssues": []
        },
        "latencyMs": 381,
        "createdAt": "2026-04-09T05:21:28.027Z",
        "usage": {
          "inputTokens": 2148,
          "outputTokens": 2885,
          "costUsd": 0.001813
        }
      },
      {
        "id": "cmnr14o2y059vp658sxk0l358",
        "runId": "cmnr14o2t059sp65808ehl9ls",
        "modelId": "gemini.3-pro",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"Equity Research AI Model v1.2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MTD\",\"currency\":\"USD\",\"current_price\":1322.76,\"target_price_6m\":1355.0,\"target_price_12m\":1390.0,\"recommendation\":\"HOLD\",\"confidence\":0.72,\"thesis_bullets\":[\"Dominant market share in precision weighing provides stable recurring revenue streams.\",\"Significant exposure to high-growth end markets like biopharma and specialty chemicals.\",\"Best-in-class operational execution and margin profile via proprietary productivity programs.\",\"Aggressive share repurchase program continues to support long-term EPS growth.\",\"Current valuation reflects premium quality but limits near-term upside potential.\"],\"key_drivers\":[{\"driver\":\"China laboratory demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biopharma R&D spending\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Raw material cost deflation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Foreign exchange fluctuations\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Interest rate environment\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"Industrial automation adoption\",\"impact\":\"MED\",\"direction\":\"POS\"}],\"risks\":[\"Geopolitical tensions impacting China operations.\",\"Slower than expected recovery in life sciences.\",\"High valuation multiple compression risk.\"],\"assumptions\":{\"revenue_cagr_3y\":0.05,\"ebit_margin_target\":0.31,\"wacc\":0.085,\"terminal_multiple\":25.0},\"scenarios\":{\"bear\":{\"target_price\":1150.0,\"prob\":0.2,\"notes\":\"Prolonged downturn in China and biopharma spending.\"},\"base\":{\"target_price\":1390.0,\"prob\":0.6,\"notes\":\"Steady execution and moderate recovery in key markets.\"},\"bull\":{\"target_price\":1550.0,\"prob\":0.2,\"notes\":\"Rapid acceleration in lab equipment replacement cycles.\"}},\"method_notes\":\"Valuation based on 30x forward P/E. HOLD reflects fair value relative to growth. Not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "Equity Research AI Model v1.2",
          "risks": [
            "Geopolitical tensions impacting China operations.",
            "Slower than expected recovery in life sciences.",
            "High valuation multiple compression risk."
          ],
          "ticker": "MTD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.6,
              "notes": "Steady execution and moderate recovery in key markets.",
              "target_price": 1390
            },
            "bear": {
              "prob": 0.2,
              "notes": "Prolonged downturn in China and biopharma spending.",
              "target_price": 1150
            },
            "bull": {
              "prob": 0.2,
              "notes": "Rapid acceleration in lab equipment replacement cycles.",
              "target_price": 1550
            }
          },
          "confidence": 0.72,
          "assumptions": {
            "wacc": 0.085,
            "revenue_cagr_3y": 0.05,
            "terminal_multiple": 25,
            "ebit_margin_target": 0.31
          },
          "key_drivers": [
            {
              "driver": "China laboratory demand",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Biopharma R&D spending",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Raw material cost deflation",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Foreign exchange fluctuations",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Interest rate environment",
              "impact": "LOW",
              "direction": "NEG"
            },
            {
              "driver": "Industrial automation adoption",
              "impact": "MED",
              "direction": "POS"
            }
          ],
          "method_notes": "Valuation based on 30x forward P/E. HOLD reflects fair value relative to growth. Not investment advice.",
          "current_price": 1322.76,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Dominant market share in precision weighing provides stable recurring revenue streams.",
            "Significant exposure to high-growth end markets like biopharma and specialty chemicals.",
            "Best-in-class operational execution and margin profile via proprietary productivity programs.",
            "Aggressive share repurchase program continues to support long-term EPS growth.",
            "Current valuation reflects premium quality but limits near-term upside potential."
          ],
          "target_price_6m": 1355,
          "target_price_12m": 1390
        },
        "errorsJson": {
          "attempts": [
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 0,
              "rawOutputTruncated": "{\"model\":\"Equity Research AI Model v1.0\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MTD\",\"currency\":\"USD\",\"current_price\":1322.76,\"target_price_6m\":1350,\"target_price_12m\":1385,\"recommendation\":\"HOLD\",\"confidence\":0.7,\"thesis_bullets\":[\"Dominant market share in precision weighing provides stable recurring revenue streams.\",\"Significant exposure to high-growth end markets like biopharma and specialty chemicals.\",\"Best-in-class operational execution and margin profile via proprietary productivity programs.\",\"Aggressive share repurchase program continues to support long-term EPS growth.\",\"Current valuation reflects premium quality but limits near-term upside potential.\"],\"key_drivers\":[{\"driver\":\"China laboratory demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biopharma R&D spending\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Raw material cost deflation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Foreign exchange fluctuations\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Interest rate environment\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"Industrial automation trends\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Replacement cycle timing\",\"impact\":\"LOW\",\"direction\":\"POS…"
            },
            {
              "error": "not_json_object: Output must be a single JSON object (no markdown/code fences, no extra text).",
              "attempt": 1,
              "rawOutputTruncated": "{\"model\":\"Equity Research AI Model v1.1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MTD\",\"currency\":\"USD\",\"current_price\":1322.76,\"target_price_6m\":1355.0,\"target_price_12m\":1390.0,\"recommendation\":\"HOLD\",\"confidence\":0.72,\"thesis_bullets\":[\"Dominant market share in precision weighing provides stable recurring revenue streams.\",\"Significant exposure to high-growth end markets like biopharma and specialty chemicals.\",\"Best-in-class operational execution and margin profile via proprietary productivity programs.\",\"Aggressive share repurchase program continues to support long-term EPS growth.\",\"Current valuation reflects premium quality but limits near-term upside potential.\"],\"key_drivers\":[{\"driver\":\"China laboratory demand\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Biopharma R&D spending\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Raw material cost deflation\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Foreign exchange fluctuations\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Interest rate environment\",\"impact\":\"LOW\",\"direction\":\"NEG\"},{\"driver\":\"Industrial automation"
            }
          ],
          "providerMeta": {
            "model": "gemini-3-flash-preview",
            "provider": "gemini",
            "webSearch": {
              "used": false,
              "allowed": false,
              "enabled": false,
              "requested": false,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 13709,
        "createdAt": "2026-04-09T05:21:28.027Z",
        "usage": {
          "inputTokens": 2824,
          "outputTokens": 480,
          "costUsd": 0.011408
        }
      },
      {
        "id": "cmnr14o2y059tp658uu3tuez2",
        "runId": "cmnr14o2t059sp65808ehl9ls",
        "modelId": "openai.gpt-5.4",
        "status": "SUCCESS",
        "rawOutput": "{\"model\":\"gpt-5\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"MTD\",\"currency\":\"USD\",\"current_price\":1322.76,\"target_price_6m\":1275,\"target_price_12m\":1365,\"recommendation\":\"HOLD\",\"confidence\":0.63,\"thesis_bullets\":[\"Premium franchise with resilient service and consumables exposure.\",\"High margins and cash flow support continued buybacks.\",\"Organic growth remains low-single-digit, capping near-term upside.\",\"Valuation is still rich versus current growth and leverage.\",\"Quality business, but shares look close to fair value.\"],\"key_drivers\":[{\"driver\":\"Service and consumables growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pricing power and product mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Pharma and bioprocess demand\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"China and industrial recovery\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Share repurchases\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Valuation multiple compression\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"FX and macro softness\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Pharma and academic capex stays weak.\",\"China recovery disappoints.\",\"Multiple compression from rates or slower growth.\",\"Leverage and low cash limit flexibility.\"],\"assumptions\":{\"revenue_cagr_3y\":6,\"ebit_margin_target\":28,\"wacc\":7.8,\"terminal_multiple\":25},\"scenarios\":{\"bear\":{\"target_price\":1150,\"prob\":0.25,\"notes\":\"Growth stays muted and valuation de-rates further.\"},\"base\":{\"target_price\":1365,\"prob\":0.5,\"notes\":\"Low-single-digit growth with steady margins supports modest appreciation.\"},\"bull\":{\"target_price\":1560,\"prob\":0.25,\"notes\":\"Demand recovery and sustained buybacks preserve premium multiple.\"}},\"method_notes\":\"Blended quality-compounder valuation using snapshot fundamentals, anchored on assumed 6% revenue CAGR, 28% EBIT margin, 7.8% WACC and 25x terminal multiple; no sell-side price targets used. HOLD fits ~3% 12M upside versus current price despite strong business quality; not investment advice.\"}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "gpt-5",
          "risks": [
            "Pharma and academic capex stays weak.",
            "China recovery disappoints.",
            "Multiple compression from rates or slower growth.",
            "Leverage and low cash limit flexibility."
          ],
          "ticker": "MTD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Low-single-digit growth with steady margins supports modest appreciation.",
              "target_price": 1365
            },
            "bear": {
              "prob": 0.25,
              "notes": "Growth stays muted and valuation de-rates further.",
              "target_price": 1150
            },
            "bull": {
              "prob": 0.25,
              "notes": "Demand recovery and sustained buybacks preserve premium multiple.",
              "target_price": 1560
            }
          },
          "confidence": 0.63,
          "assumptions": {
            "wacc": 7.8,
            "revenue_cagr_3y": 6,
            "terminal_multiple": 25,
            "ebit_margin_target": 28
          },
          "key_drivers": [
            {
              "driver": "Service and consumables growth",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pricing power and product mix",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Pharma and bioprocess demand",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "China and industrial recovery",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Share repurchases",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Valuation multiple compression",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "FX and macro softness",
              "impact": "MED",
              "direction": "NEG"
            }
          ],
          "method_notes": "Blended quality-compounder valuation using snapshot fundamentals, anchored on assumed 6% revenue CAGR, 28% EBIT margin, 7.8% WACC and 25x terminal multiple; no sell-side price targets used. HOLD fits ~3% 12M upside versus current price despite strong business quality; not investment advice.",
          "current_price": 1322.76,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Premium franchise with resilient service and consumables exposure.",
            "High margins and cash flow support continued buybacks.",
            "Organic growth remains low-single-digit, capping near-term upside.",
            "Valuation is still rich versus current growth and leverage.",
            "Quality business, but shares look close to fair value."
          ],
          "target_price_6m": 1275,
          "target_price_12m": 1365
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "openai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "resp_0d98ff081fcdd4cd0069d75b9f27448194b3b27619dfc8c008",
            "reasoningEffort": "medium",
            "structuredOutputs": {
              "used": true,
              "requested": true,
              "disabledReason": null
            }
          },
          "sanityIssues": []
        },
        "latencyMs": 35043,
        "createdAt": "2026-04-09T05:21:28.027Z",
        "usage": {
          "inputTokens": 2417,
          "outputTokens": 2043,
          "costUsd": 0.032832
        }
      },
      {
        "id": "cmnr14o2y059wp658ltagmles",
        "runId": "cmnr14o2t059sp65808ehl9ls",
        "modelId": "xai.grok-4.20-reasoning",
        "status": "SUCCESS",
        "rawOutput": "{\n  \"model\": \"DCF Valuation Model\",\n  \"as_of\": \"2026-04-08T20:00:02.000Z\",\n  \"ticker\": \"MTD\",\n  \"currency\": \"USD\",\n  \"current_price\": 1322.76,\n  \"target_price_6m\": 1360,\n  \"target_price_12m\": 1400,\n  \"recommendation\": \"HOLD\",\n  \"confidence\": 0.62,\n  \"thesis_bullets\": [\n    \"Strong leadership in precision instruments and analytics\",\n    \"High margins offset by modest 4% revenue growth\",\n    \"Aggressive buybacks support EPS despite weak ROE\",\n    \"Premium 33x PE leaves little room for disappointment\",\n    \"Mixed demand in pharma and industrial end markets\"\n  ],\n  \"key_drivers\": [\n    {\n      \"driver\": \"Pharma and lab capex recovery\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"China and Asia demand trends\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Share repurchase program\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Valuation multiple contraction\",\n      \"impact\": \"HIGH\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Product innovation and pricing\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Industrial cyclical exposure\",\n      \"impact\": \"MED\",\n      \"direction\": \"NEG\"\n    },\n    {\n      \"driver\": \"Supply chain and FX stability\",\n      \"impact\": \"MED\",\n      \"direction\": \"POS\"\n    },\n    {\n      \"driver\": \"Competitive technology shifts\",\n      \"impact\": \"LOW\",\n      \"direction\": \"NEG\"\n    }\n  ],\n  \"risks\": [\n    \"Prolonged weakness in pharma spending\",\n    \"Further de-rating from high valuation\",\n    \"China market or geopolitical risks\",\n    \"FX headwinds from strong dollar\",\n    \"Margin pressure from cost inflation\"\n  ],\n  \"assumptions\": {\n    \"revenue_cagr_3y\": 0.045,\n    \"ebit_margin_target\": 0.26,\n    \"wacc\": 0.082,\n    \"terminal_multiple\": 28\n  },\n  \"scenarios\": {\n    \"bear\": {\n      \"target_price\": 1100,\n      \"prob\": 0.3,\n      \"notes\": \"Weak demand persists and multiple contracts.\"\n    },\n    \"base\": {\n      \"target_price\": 1400,\n      \"prob\": 0.5,\n      \"notes\": \"Steady growth and buybacks yield modest upside.\"\n    },\n    \"bull\": {\n      \"target_price\": 1720,\n      \"prob\": 0.2,\n      \"notes\": \"Accelerated demand and innovation drive re-rating.\"\n    }\n  },\n  \"method_notes\": \"DCF using 4.5% rev CAGR, 26% EBIT margin, 8.2% WACC and 28x terminal. ~6% upside supports HOLD per rubric. Snapshot data used exclusively for price/fundamentals. not investment advice.\"\n}",
        "parsedJson": {
          "as_of": "2026-04-08T20:00:02.000Z",
          "model": "DCF Valuation Model",
          "risks": [
            "Prolonged weakness in pharma spending",
            "Further de-rating from high valuation",
            "China market or geopolitical risks",
            "FX headwinds from strong dollar",
            "Margin pressure from cost inflation"
          ],
          "ticker": "MTD",
          "currency": "USD",
          "scenarios": {
            "base": {
              "prob": 0.5,
              "notes": "Steady growth and buybacks yield modest upside.",
              "target_price": 1400
            },
            "bear": {
              "prob": 0.3,
              "notes": "Weak demand persists and multiple contracts.",
              "target_price": 1100
            },
            "bull": {
              "prob": 0.2,
              "notes": "Accelerated demand and innovation drive re-rating.",
              "target_price": 1720
            }
          },
          "confidence": 0.62,
          "assumptions": {
            "wacc": 0.082,
            "revenue_cagr_3y": 0.045,
            "terminal_multiple": 28,
            "ebit_margin_target": 0.26
          },
          "key_drivers": [
            {
              "driver": "Pharma and lab capex recovery",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "China and Asia demand trends",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Share repurchase program",
              "impact": "HIGH",
              "direction": "POS"
            },
            {
              "driver": "Valuation multiple contraction",
              "impact": "HIGH",
              "direction": "NEG"
            },
            {
              "driver": "Product innovation and pricing",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Industrial cyclical exposure",
              "impact": "MED",
              "direction": "NEG"
            },
            {
              "driver": "Supply chain and FX stability",
              "impact": "MED",
              "direction": "POS"
            },
            {
              "driver": "Competitive technology shifts",
              "impact": "LOW",
              "direction": "NEG"
            }
          ],
          "method_notes": "DCF using 4.5% rev CAGR, 26% EBIT margin, 8.2% WACC and 28x terminal. ~6% upside supports HOLD per rubric. Snapshot data used exclusively for price/fundamentals. not investment advice.",
          "current_price": 1322.76,
          "recommendation": "HOLD",
          "thesis_bullets": [
            "Strong leadership in precision instruments and analytics",
            "High margins offset by modest 4% revenue growth",
            "Aggressive buybacks support EPS despite weak ROE",
            "Premium 33x PE leaves little room for disappointment",
            "Mixed demand in pharma and industrial end markets"
          ],
          "target_price_6m": 1360,
          "target_price_12m": 1400
        },
        "errorsJson": {
          "attempts": [],
          "providerMeta": {
            "provider": "xai",
            "webSearch": {
              "used": false,
              "enabled": false,
              "sources": [],
              "maxToolCalls": 2
            },
            "responseId": "8394d9b7-6128-978a-910f-5644b5fd992c",
            "usedFallbackChatCompletions": false
          },
          "sanityIssues": []
        },
        "latencyMs": 21885,
        "createdAt": "2026-04-09T05:21:28.027Z",
        "usage": {
          "inputTokens": 2755,
          "outputTokens": 3720,
          "costUsd": 0.064065
        }
      }
    ]
  }
}